Multidisciplinary Management of Lung Cancer

Alexander I. Spira(Sidney Kimmel Comprehensive Cancer Center), David S. Ettinger(Sidney Kimmel Comprehensive Cancer Center)
New England Journal of Medicine
January 21, 2004
10.1056/nejmra035536
Cited by 925

Abstract

Despite years of research, the five-year survival rate among patients with lung cancer is a mere 14 percent. Lung cancer is divided into two major types — non–small-cell lung cancer and the more aggressive small-cell lung cancer. This review considers the treatment of each type in the framework of multidisciplinary management and recent clinical trials.

Related Papers

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al.|Journal of Clinical Oncology|2000|1.4k
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials
Sarah Burdett, Mkb Parmar, Lesley Stewart et al.|The Lancet|1998|837
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
Nevin Murray, P. Coy, Joseph L. Pater et al.|Journal of Clinical Oncology|1993|726
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Alan B. Sandler, John Nemunaitis, Claude Denham et al.|Journal of Clinical Oncology|2000|719
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
Philip Bonomi, KyungMann Kim, Diane L. Fairclough et al.|Journal of Clinical Oncology|2000|594